ClinicalTrials.Veeva

Menu

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

A

AlzeCure Pharma

Status and phase

Completed
Phase 1

Conditions

Alzheimer Disease
Cognition Disorder

Treatments

Drug: ACD856
Drug: ACD856 (fed cohort)
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05077631
D2000CI-001

Details and patient eligibility

About

The SAD design of the study is based on the aim to study safety, tolerability and PK of selected doses of ACD856 in a limited number of healthy volunteers. ACD856 will be administered orally.

Enrollment

56 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Signed and dated informed consent prior to any study-mandated procedure.´
  • Willing and able to comply with study requirements.
  • Healthy males and healthy women of non-childbearing potential aged ≥18 and <65 years at screening.
  • BMI ≥18.0 and ≤30.0 kg/m2 at screening.
  • Males and females of non-childbearing potential may be included in the study. Male subjects must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP.
  • Clinically acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.

Exclusion criteria

  • Planned treatment or treatment with another investigational drug within 3 months prior to randomization.
  • Positive screen for drugs of abuse or a positive alcohol result at screening or admission to the clinic.
  • Clinically relevant findings in laboratory parameters, ECG or vital signs at screening
  • Current smokers or users of nicotine products.
  • History of alcohol abuse or excessive intake of alcohol.
  • Presence or history of drug abuse.
  • History of, or current use of, anabolic steroids.
  • Excessive caffeine consumption.
  • Plasma donation within one month of screening or blood donation prior to screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

56 participants in 2 patient groups, including a placebo group

ACD856
Experimental group
Treatment:
Drug: ACD856
Drug: ACD856 (fed cohort)
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems